tbuckley/cabot-search huggingface dataset:
Total Therapies (TT) for Newly Diagnosed Patients with Multiple Myeloma (MM): Significant Benefit in High-Risk Disease with Cytogenetic Abnormalities (CA) over the Course of 17 Years.
Authors: Frits van Rhee, Vanessa Bolejack, Elias Anaissie, Guido Tricot, Klaus Hollmig, Maurizio Zangari, Mauricio Pineda-Roman, Abid Mohiuddin, Antje Hoering, John Crowley, Bart Barlogie
Journal: Blood (2006)
Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate data
Authors: Meredith S Shiels, Pavel Chernyavskiy, William F Anderson, Ana F Best, Emily A Haozous, Patricia Hartge, Philip S Rosenberg, David Thomas, Neal D Freedman, Amy Berrington de Gonzalez
Journal: The Lancet (2017)
Re: Jakob Damsgaard, Ulla N. Joensen, Elisabeth Carlsen, et al. Varicocele Is Associated with Impaired Semen Quality and Reproductive Hormone Levels: A Study of 7035 Healthy Young Men from Six European Countries. Eur Urol 2016;70:1019–29
Authors: Eugenio Ventimiglia, Francesco Montorsi, Andrea Salonia
Journal: European Urology (2016)
Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?.
Authors: Eva Fronkova, Smadar Avigad, Ki Wai Chik, Luis Castillo, Manor Sigal, Leona Reznickova, Katerina Zdrahalova, Tatana Skocovska, Martin Schrappe, Valentino Conter, Shai Izraeli, Chi Kong Li, Batia Stark, Ondrej Hrusak, Ester Mejstrikova, Jan Stary, Jan Trka
Journal: Blood (2006)
T Cell Responses Directed Against HLA A*0201-Restricted Epitopes Derived from WT1 Are Readily Identifiable in Patients with AML and CML, but Not in Patients with ALL.
Authors: Katayoun Rezvani, Jason Brenchley, David Price, Yasemin Kilical, Matthias Grube, Emma Gostick, Yong Tang, Giuseppe Sconocchia, Hiroshi Fujiwara, Elaine Sloand, Daniel C. Douek, John Barrett
Journal: Blood (2004)
Sanctioned UK Trial of Mitochondrial Transfer Nears
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 13050: Gender Differences in the Implementation of Secondary Prevention in Patients With Coronary Heart Disease: Results From the EUROASPIRE IV Survey
Authors: Kornelia Kotseva, Delphine De Smedt, David Wood, Dirk De Bacquer
Journal: Circulation (2015)

Objective: To describe gender differences in lifestyle and risk factor management, and the use of cardioprotective drug therapies in patients with coronary heart disease in Europe. Methods: The EUROASPIRE IV survey was a cross-sectional study carried out under the auspices of the European Society of Cardiology, EURObservational Research Programme in 2012-2013 in 78 centers in 24 European countries. Consecutive patients &lt;80 years after acute coronary syndrome or revascularization were identified from hospital records and interviewed and examined at least 6 months later using standardized methods and instruments. Results: A total of 7998 patients (24.4% females) were interviewed on average 16 months after having experienced a cardiac event. Women were older (mean age 66.3 years [SD 9.0] vs 63.2 [9.7], p&lt;0.001), had a lower level of education, and had more often unstable angina (14.4% vs 9%, p&lt;0.001) at inclusion than men. Comparing women with men, the prevalence of the risk factors were as follows (p-values adjusted for age and center): current smoking 11.1% vs 17.6% (p&lt;0.001), obesity (BMI ≥ 30 kg/m2) 43.8% vs 35.6% (p&lt;0.001), central obesity (waist circumference ≥ 102 cm in men or ≥ 88 cm in women) 75.2% vs 52.8% (p&lt;0.001), raised blood pressure (BP ≥ 140/90 mmHg, ≥ 140/80 mmHg in patients with diabetes) 43.8% vs 42.4%, (p=0.662), elevated LDL-cholesterol (≥ 1.8 mmol/l) 84.4% vs 79.2% (p&lt;0.001) and self reported diabetes 30.1% vs 25.7% (p=0.013). Reported use of prophylactic drug therapies for the same comparison was: antiplatelets 92.4% vs. 94.3% (p=0.102); beta-blockers 82.5% vs. 82.6% (p=0.858); ACE inhibitors/ARBs 74.6% vs. 75.3% (p=0.187); and statins 83.5% vs. 86.4% (p=0.039). The therapeutic control of blood pressure, LDL-cholesterol and diabetes (HbA1c &lt; 7 mmol/L) was: 53.7% vs 53.1% (p=0.171), 17.3% vs 22.3% (p&lt;0.001) and 49.2% vs 53.8% (p=0.015), respectively. Conclusion: The results show that women with coronary heart disease have higher prevalence of obesity, central obesity, LDL-cholesterol and self-reported diabetes than men. Despite similarities in pharmacological treatment women reach less often than men the therapeutic goals of LDL-cholesterol after acute coronary event or revascularization.
Autologous Serum Containing Platelet Derived Growth Factors (PDGFs) as Topical Treatment for “Sicca Syndrome” Associated with Chronic GvHD.
Authors: Del Fante Claudia, Perotti Cesare, Viarengo Gianluca, Marchesi Andrea, Parisi Cristina, Bergamaschi Paola, Salvaneschi Laura
Journal: Blood (2006)
Cellular Model of Colon Cancer Progression Reveals Signatures of mRNAs, miRNA, lncRNAs, and Epigenetic Modifications Associated with Metastasis
Authors: Matjaz Rokavec, David Horst, Heiko Hermeking
Journal: Cancer Research (2017)

Here, we developed and comprehensively characterized a cellular model of colon cancer progression consisting of four defined derivatives of a colon cancer cell line that resulted from consecutive epithelial-mesenchymal and mesenchymal-epithelial transitions (EMT/MET) and phenotypically recapitulate the metastatic cascade. Initial EMT was induced by prolonged exposure to IL6, a cytokine also generated by the tumor-stroma. Genome-wide characterization of transcriptional (mRNA, miRNA, and lncRNA) and epigenetic (DNA methylation, H3K4me3, H3K79me3, and H3K27me3 histone modifications) profiles of the cell derivatives, combined with correlative analyses of expression, methylation, and clinical data from the TCGA-COAD database gave insights into the molecular basis of their phenotypic changes. The signatures characterizing invasive, mesenchymal-like cell states as well as the metastases-derived epithelial-like state showed significant association with metastasis, positive nodal status, and poor survival of colon cancer patients. Global hypomethylation of gene-regulatory regions was observed during tumor progression, with the lowest degree of methylation present in cells isolated from metastases. Upregulation of an axon-guidance-related gene signature was the most significant feature of metastatic tumor cells and was also found in primary tumors from colon cancer patients with distant metastases. Furthermore, the microRNAs miR-99a, miR-100, and miR-125b showed elevated expression in mesenchymal-like cells, associated with poor survival, and promoted migration and invasion. Finally, elevated expression of H19 lncRNA due to promoter demethylation was observed in cells isolated from metastases and was associated with poor survival of colon cancer patients. In the future, our results may be further exploited for the discovery and evaluation of novel metastasis-associated mechanisms and biomarkers. Cancer Res; 77(8); 1854-67. ©2017 AACR.
Family History of Cancer and Risk of Lymphoma: Influence of IL8RB, GGH IVS7 and IL10 Polymorphisms.
Authors: Eva Domingo-Domènech, Yolanda Benavente, Carlos Montalbán, Ramon Bosch, Josep Gumà, Sophia Wang, Nathaniel Rothman, Eva Gonzalez-Barca, Silvia de Sanjose
Journal: Blood (2008)
Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol – A Prospective Clinical Trial by the Grupo Español de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats L Brune, Jakob R. Passweg, Joan Besalduch, Rafael F Duarte, Angel Leon, Maria Jesus Pascual, Norbert Schmitz
Journal: Blood (2009)
Expression Profiling of ABC-Transporters in Childhood AML Reveals ABCA3 as a Potential Cause of Drug Resistance.
Authors: Daniel Steinbach, Jean-Pierre Gillet, Axel Sauerbrey, Bernd Gruhn, Kristin Dawczynski, Francoise de Longueville, Vincent Bertholet, Felix Zintl, Jose Remacle, Thomas Efferth
Journal: Blood (2004)
Effects of Arsenic Trioxide on Megakaryocytic Cell Lines: Apoptosis, Cell Cycle Dysfunction and Signaling Pathways.
Authors: Hubert K.B. Lam, Karen K.H. Li, Ki Wai Chik, Mo Yang, Carmen K.Y. Chuen, Venus C.T. Liu, Chi Kong Li, Matthew M.K. Shing, Patrick M.P. Yuen
Journal: Blood (2004)
Loss of executive function after dialysis initiation in adults with chronic kidney disease
Authors: Manjula Kurella Tamura, Eric Vittinghoff, Chi-yuan Hsu, Karman Tam, Stephen L. Seliger, Stephen Sozio, Michael Fischer, Jing Chen, Eva Lustigova, Louise Strauss, Rajat Deo, Alan S. Go, Kristine Yaffe, Lawrence J. Appel, Harold I. Feldman, Alan S. Go, Jiang He, John W. Kusek, James P. Lash, Akinlolu Ojo, Mahboob Rahman, Raymond R. Townsend
Journal: Kidney International (2017)
Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202
Authors: Sonali M. Smith, Brandelyn Pitcher, Sin-Ho Jung, Nancy L. Bartlett, Nina Wagner-Johnston, Steven I. Park, Kristy L. Richards, Amanda F. Cashen, Bruce D. Cheson, John P. Leonard
Journal: Blood (2014)
Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution
Authors: Maarten van Iterson, Erik W. van Zwet, Bastiaan T. Heijmans
Journal: Genome biology (2017)

We show that epigenome- and transcriptome-wide association studies (EWAS and TWAS) are prone to significant inflation and bias of test statistics, an unrecognized phenomenon introducing spurious findings if left unaddressed. Neither GWAS-based methodology nor state-of-the-art confounder adjustment methods completely remove bias and inflation. We propose a Bayesian method to control bias and inflation in EWAS and TWAS based on estimation of the empirical null distribution. Using simulations and real data, we demonstrate that our method maximizes power while properly controlling the false positive rate. We illustrate the utility of our method in large-scale EWAS and TWAS meta-analyses of age and smoking.
Use of CT and Chest Radiography for Lung Cancer Screening Before and After Publication of Screening Guidelines
Authors: Jinhai Huo, Chan Shen, Robert J. Volk, Ya-Chen Tina Shih
Journal: JAMA Internal Medicine (2017)

Linda S. Kinsinger, MD, MPH; Charles Anderson, MD, PhD; Jane Kim, MD, MPH; Martha Larson, BSN, MS; Stephanie H. Chan, MPH; Heather A. King, PhD; Kathryn L. Rice, MD; Christopher G. Slatore, MD, MS; Nichole T. Tanner, MD, MSCR; Kathleen Pittman, BSN, MPH; Robert J. Monte, MBA; Rebecca B. McNeil, PhD; Janet M. Grubber, MSPH; Michael J. Kelley, MD; Dawn Provenzale, MD, MSc; Santanu K. Datta, PhD; Nina S. Sperber, PhD; Lottie K. Barnes, MPH; David H. Abbott, MS; Kellie J. Sims, PhD, MS; Richard L. Whitley, BS; R. Ryanne Wu, MD, MHS; George L. Jackson, PhD, MHA
Long-Term WT1 Peptide Vaccination Over 7 Years for 3 AML Patients with Molecular Relapse
Authors: Haruo Sugiyama, Akihiro Tsuboi, Yoshihiro Oka, Taiichi Kyo, Yuuta Katayama, Elisseeva Olga, Manabu Kawakami, Naoki Hosen, Sumiyuki Nishida, Soyoko Morimoto, Ayako Murao, Hiroko Nakajima, Ichiro Kawase, Yusuke Oji, Hiroo Dohy
Journal: Blood (2010)
The Expression of the Adaptor Protein SLP-65 Is Freqently Lost in Childhood B-Lineage Acute Lymphoblastic Leukemia (ALL).
Authors: Arndt Borkhardt, Christine Damm-Welk, Jochen Harbott, Thomas Wossning, Bettina Storch, Uta Fuchs, Martin Zimmermann, Susanne Viehmann, Wolf-Dieter Ludwig, Martin Schrappe, Hassan Jumaa
Journal: Blood (2004)
Symptom Burden Characteristics Among Chinese Patients with Myeloproliferative Neoplasms (MPNs)
Authors: Zhijian Xiao, Robyn M. Emanuel, Amylou C. Dueck, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Holly Lynn Geyer, Robert Peter Gale, Ruben A. Mesa
Journal: Blood (2012)
Three shortlisted candidates bid to lead WHO
Authors: Anne Gulland
Journal: BMJ (2017)

The World Health Organization has unveiled its shortlist of candidates in the running to take over from Margaret Chan as its next director general.

The six longlisted candidates gave presentations to WHO’s executive board in Geneva earlier this week and were then whittled down to the final three:

In May the World Health Assembly will vote to elect the winning candidate, who is due to take up the position on 1 July.

The three candidates gave presentations …
Unrelated Donor Umbilical Cord Blood Transplantation in Children with Acquired Aplastic Anemia. Korean Experience of 12 Cases.
Authors: Hoon Kook, Hee-Jo Baek, Tai-Ju Hwang, Hong-Hoe Koo, Keon-Hee Yoo, Ki-Woong Sung, Young-Ho Lee, Jong-Jin Seo, Ho-Jun Im, Bin Cho, Hack-Ki Kim, Heung-Sik Kim, Jun-Eun Park, Hyoung Jin Kang, Hee-Young Shin, Hyo-Seop Ahn
Journal: Blood (2006)
Nicotinamide reduces cyclooxygenase-2 expression in HaCaT keratinocytes after ultraviolet-B irradiation
Authors: G. Monfrecola, R. Di Caprio, N. Balato, M. A. Bevilacqua, B. Iovine, S. Lembo, A. Balato
Journal: British Journal of Dermatology (2017)

In their interesting research letter, Chen et al. (2016 Apr 8. doi: 10.1111/bjd.14662)1 described the protective effects of oral nicotinamide (NCT) for chemoprevention of non-melanoma skin cancers (NMSCs) in renal transplant recipients. We totally agree that NCT can represent a new opportunity

for NMSC chemoprevention basing on its capability to preserve cellular energy reserve for ATP-dependent DNA repair as well as UV-induced immunosuppression.2 Moreover, we hypothesize that one of the mechanisms through which NCT may act is by modulating the expression of cyclooxygenase (COX)-2, the rate-limiting enzyme in prostaglandin (PG) generation.

This article is protected by copyright. All rights reserved.
Prospective phase II study of chemoembolization with drug-eluting beads for hepatic neuroendocrine metastases: Interim analysis.
Authors: D. K. Reyes, I. R. Kamel, C. Georgiades, K. Hong, N. Bhagat, J. H. Geschwind
Journal: Journal of Clinical Oncology (2011)

331 Background: To evaluate safety and efficacy of transarterial chemoembolization with doxorubicin eluting beads (DEB-TACE) in 30 patients with hepatic neuroendocrine metastases (NET) in a prospective phase II study. We report the interim analysis on 10 patients. Methods: Patients who met inclusion criteria (NET liver-dominant metastases, ECOG 0-1, treatment naïve) underwent up to 4 DEB-TACE sessions (100-300 micron beads loaded with up to 100mg of doxorubicin) within a 6-month period. Statistical plan included interim analysis of initial 10 patients to assess therapeutic efficacy (defined as objective response≥50%). Tumor response was assessed by MR imaging 1 month after treatment using contrast-enhancement (EASL) and tumor size (RECIST). Safety was assessed by NCI Common Terminology Criteria. Results: DEB-TACE was successfully performed in 10 patients (22 targeted lesions). Patient characteristics included mean age 65 yrs; ECOG 0/1 (6/4); carcinoid syndrome (n=2); tumor burden range (4-75%), and mean targeted tumor size 4.8 cm (range 1.2-10.2). At one month follow-up (n=9), Grade 3 toxicities consisted of hyperglycemia (n=3), abdominal pain (n=3), fatigue (n=1), biloma (n=1) and elevated ALT (n=1). Note that four patients had Grade 2 bilomas, which occurred in the setting of small lesions (&lt;2cm), diffuse disease with very low tumor burden (near military pattern), and single lesion ≥ 5cm. Tumor response using MR imaging at 1 month-follow-up revealed a mean treated tumor decrease in size of 7% (p=0.03), and a mean decrease in contrast-enhancement of 59% (p&lt;0.0001). Using RECIST, partial response was achieved in 1 patient (11%), whereas 8 patients (89%) had stable disease. Using EASL criteria, 7 patients (78%) had objective tumor response and 2 (12%) had stable disease. Conclusions: Interim analysis shows therapeutic efficacy of DEB-TACE in liver-dominant NET metastases. Early recommendation suggests DEB-TACE may be best suited for NET patients with multifocal disease or diffuse disease with large tumor burden. [Table: see text] No significant financial relationships to disclose.
Margaret McCartney: Swapping systematic reviews for celebrity endorsements
Authors: Margaret McCartney
Journal: BMJ (2017)

The actor Ben Stiller has written an essay on prostate specific antigen screening, called Taking the PSA Test Saved My Life . He finishes by saying, “I believe the best way to determine a course of action for the most treatable, yet deadly cancer, is to detect it early.” The piece prompted widespread, mainly uncritical, media coverage.1

The social media star Kim Kardashian promoted Diclegis, a tablet promoted for morning sickness in Canada, on her Instagram feed. The US Food and Drug Administration subsequently told its manufacturers to take “corrective …
Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease
Authors: Brian D. Modena, Eugene R. Bleecker, William W. Busse, Serpil C. Erzurum, Benjamin M. Gaston, Nizar N. Jarjour, Deborah A. Meyers, Jadranka Milosevic, John R. Tedrow, Wei Wu, Naftali Kaminski, Sally E. Wenzel
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Severe asthma (SA) is a heterogeneous disease with multiple molecular mechanisms. Gene expression studies of bronchial epithelial cells in individuals with asthma have provided biological insight and underscored possible mechanistic differences between individuals.Identify networks of genes reflective of underlying biological processes that define SA.Airway epithelial cell gene expression from 155 subjects with asthma and healthy control subjects in the Severe Asthma Research Program was analyzed by weighted gene coexpression network analysis to identify gene networks and profiles associated with SA and its specific characteristics (i.e., pulmonary function tests, quality of life scores, urgent healthcare use, and steroid use), which potentially identified underlying biological processes. A linear model analysis confirmed these findings while adjusting for potential confounders.Weighted gene coexpression network analysis constructed 64 gene network modules, including modules corresponding to T1 and T2 inflammation, neuronal function, cilia, epithelial growth, and repair mechanisms. Although no network selectively identified SA, genes in modules linked to epithelial growth and repair and neuronal function were markedly decreased in SA. Several hub genes of the epithelial growth and repair module were found located at the 17q12-21 locus, near a well-known asthma susceptibility locus. T2 genes increased with severity in those treated with corticosteroids but were also elevated in untreated, mild-to-moderate disease compared with healthy control subjects. T1 inflammation, especially when associated with increased T2 gene expression, was elevated in a subgroup of younger patients with SA.In this hypothesis-generating analysis, gene expression networks in relation to asthma severity provided potentially new insight into biological mechanisms associated with the development of SA and its phenotypes.
Treatment of recurrent esophageal stricture with an insulated-tip electrosurgical knife and mitomycin C
Authors: Austin Chiang, Wasif Abidi, Christopher Thompson
Journal: Endoscopy (2017)

An 82-year-old woman presented with dysphagia due to a refractory esophageal stricture. The stricture was thought to have been caused 2 years previously after hospitalization for a hip fracture and prolonged nasogastric tube placement at a subacute care facility. Numerous attempts at stricture dilation, initially every 2 weeks, had been made at another institution using a hydrostatic balloon and an esophageal stent, which was later removed because of complications.
Bcl-2 Family Protein Inhibitors Induce a Unique Thrombocytopenia In Vivo.
Authors: Steven W. Elmore, Joy Bauch, Ryan M. Fryer, Laurie Iciek, Kennan Marsh, Sherry J. Morgan, Richard Nelson, Glenn A. Reinhart, Morey L. Smith, Chris Tse, Saul H. Rosenberg
Journal: Blood (2006)
BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management
Authors: J.H. Wu, D.N. Cohen, P.L. Rady, S.K. Tyring
Journal: British Journal of Dermatology (2017)

Mutations in the BRAF proto‐oncogene occur in the majority of cutaneous melanomas. The commonly detected valine (V) to glutamate (E) mutation (V600E) is known to drive melanomagenesis and has thus been the target of two highly selective chemotherapeutic agents: vemurafenib and dabrafenib. While BRAF inhibitor therapy has revolutionized the treatment of metastatic melanoma, unanticipated cutaneous toxicities, including the development of cutaneous squamous cell carcinomas (cSCCs), are frequently reported and hinder therapeutic durability. However, the mechanisms by which BRAF inhibitors induce cutaneous neoplasms are poorly understood, thus posing a challenge for specific therapies. In this review, we summarize the clinical and molecular profiles of BRAF inhibitor‐associated cSCCs, with a focus on factors that may contribute to disease pathogenesis. In particular, we discuss the emerging evidence pointing towards viral involvement in BRAF inhibitor‐induced cutaneous neoplasms and offer new perspectives on future therapeutic interventions. Continued clinical and mechanistic studies along this line will not only allow for better understanding of the pathogenic progression of BRAF inhibitor‐induced cSCCs, but will also lead to development of new therapeutic and preventative options for patients receiving targeted cancer therapy.